Search

Your search keyword '"Dellinger MT"' showing total 32 results

Search Constraints

Start Over You searched for: Author "Dellinger MT" Remove constraint Author: "Dellinger MT"
32 results on '"Dellinger MT"'

Search Results

2. A single-cell atlas of normal and KRASG12D-malformed lymphatic vessels.

Catalog

Books, media, physical & digital resources

3. Stepwise Ultra-pH-Sensitive Micelles Overcome a p K a Barrier for Systemic Lymph Node Delivery.

4. Trametinib inhibits lymphatic vessel invasion of bone in a mouse model of Gorham-Stout disease.

5. Hyperactive KRAS/MAPK signaling disrupts normal lymphatic vessel architecture and function.

6. Heterozygous Mutation of Vegfr3 Reduces Renal Lymphatics without Renal Dysfunction.

7. KRAS-driven model of Gorham-Stout disease effectively treated with trametinib.

8. The emergence of targetable MEKanisms in sporadic lymphatic disorders.

9. Lymphatics in bone arise from pre-existing lymphatics.

10. Impaired meningeal lymphatic vessel development worsens stroke outcome.

11. Bone development and fracture healing is normal in mice that have a defect in the development of the lymphatic system.

12. Somatic activating mutations in PIK3CA cause generalized lymphatic anomaly.

13. Cyclooxygenase-2 Inhibition Potentiates the Efficacy of Vascular Endothelial Growth Factor Blockade and Promotes an Immune Stimulatory Microenvironment in Preclinical Models of Pancreatic Cancer.

14. Lymphangiogenesis, lymphatic systemomics, and cancer: context, advances and unanswered questions.

15. Mir-126 is a conserved modulator of lymphatic development.

16. VEGF-C promotes the development of lymphatics in bone and bone loss.

17. Hyperplasia, de novo lymphangiogenesis, and lymphatic regression in mice with tissue-specific, inducible overexpression of murine VEGF-D.

18. Identification of Gene Expression Differences between Lymphangiogenic and Non-Lymphangiogenic Non-Small Cell Lung Cancer Cell Lines.

19. Warfarin Blocks Gas6-Mediated Axl Activation Required for Pancreatic Cancer Epithelial Plasticity and Metastasis.

20. Actions of the protein kinase WNK1 on endothelial cells are differentially mediated by its substrate kinases OSR1 and SPAK.

21. Viewpoints on vessels and vanishing bones in Gorham-Stout disease.

22. Collagen signaling enhances tumor progression after anti-VEGF therapy in a murine model of pancreatic ductal adenocarcinoma.

23. Vascular endothelial growth factor receptor-2 promotes the development of the lymphatic vasculature.

24. RHOA-FAK is a required signaling axis for the maintenance of KRAS-driven lung adenocarcinomas.

25. Stromal platelet-derived growth factor receptor α (PDGFRα) provides a therapeutic target independent of tumor cell PDGFRα expression in lung cancer xenografts.

26. Overlapping biomarkers, pathways, processes and syndromes in lymphatic development, growth and neoplasia.

27. Connexin37 and Connexin43 deficiencies in mice disrupt lymphatic valve development and result in lymphatic disorders including lymphedema and chylothorax.

28. Lymphangiogenesis and hemangiogenesis: potential targets for therapy.

29. Phosphorylation of Akt and ERK1/2 is required for VEGF-A/VEGFR2-induced proliferation and migration of lymphatic endothelium.

30. Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts.

31. Novel FOXC2 missense mutation identified in patient with lymphedema-distichiasis syndrome and review.

32. Chy-3 mice are Vegfc haploinsufficient and exhibit defective dermal superficial to deep lymphatic transition and dermal lymphatic hypoplasia.